Literature DB >> 21385926

Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.

Maxim A Moroz1, Ruimin Huang, Tatiana Kochetkov, Weiji Shi, Howard Thaler, Elisa de Stanchina, Idoia Gamez, Robert P Ryan, Ronald G Blasberg.   

Abstract

UNLABELLED: PURPOSE/EXPERIMENTAL
DESIGN: Treatment of cerebral tumors and peritumoral brain edema remains a clinical challenge and is associated with high morbidity and mortality. Dexamethasone is an effective drug for treating brain edema, but it is associated with well-documented side effects. Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide.
RESULTS: In vitro combination therapy and monotherapy showed a variable response in 6 different glioma cell lines. In vivo studies showed a dose-dependent effect of hCRF (0.03 and 0.1 mg/kg q12h) on survival of U87 intracranial xenograft-bearing animals [median survival: control--41 days (95% CI 25-61); "low-hCRF" 74.5 days (95% CI 41-88); "high-hCRF" >130 days (95% CI not reached)]. Dexamethasone treatment had no effect on survival, but significant toxicity was observed. A survival benefit was observed with temozolomide and temozolomide + hCRF-treated animals but with significant temozolomide toxicity. C6-bearing animals showed no survival benefit, but there were similar treatment toxicities. The difference in hCRF treatment response between U87 and C6 intracranial gliomas can be explained by a difference in receptor expression. RT-PCR identified CRF2r mRNA in U87 xenografts; no CRF receptors were identified in C6 xenografts.
CONCLUSIONS: hCRF was more effective than either dexamethasone or temozolomide in the treatment of U87 xenografts, and results included improved prognosis with long-term survivors and only mild toxicity. The therapeutic efficacy of hCRF seems to be dependent on tumor hCRF receptor (CRFr) expression. These results support further clinical assessment of the therapeutic efficacy of hCRF and levels of CRFr expression in different human gliomas. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385926      PMCID: PMC3131845          DOI: 10.1158/1078-0432.CCR-10-3203

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway.

Authors:  J Tjuvajev; Y Kolesnikov; R Joshi; J Sherinski; L Koutcher; Y Zhou; C Matei; J Koutcher; M J Kreek; R Blasberg
Journal:  In Vivo       Date:  1998 Jan-Feb       Impact factor: 2.155

2.  Anti-inflammatory activity of corticotropin releasing factor: II. Mechanisms of action.

Authors:  J G Kiang; L Poree; E T Wei
Journal:  Proc West Pharmacol Soc       Date:  1987

3.  Anti-inflammatory activity of corticotropin releasing factor: I. Efficacy studies.

Authors:  E T Wei; J G Kiang; J Q Tian
Journal:  Proc West Pharmacol Soc       Date:  1987

4.  Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.

Authors:  K W Carlson; S S Nawy; E T Wei; W Sadée; V A Filov; V V Rezsova; A Slominski; J M Quillan
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

5.  A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.

Authors:  M A Villalona-Calero; J Eckardt; H Burris; M Kraynak; S Fields-Jones; C Bazan; J Lancaster; T Hander; R Goldblum; L Hammond; A Bari; R Drengler; M Rothenberg; G Hadovsky; D D Von Hoff
Journal:  Ann Oncol       Date:  1998-01       Impact factor: 32.976

6.  Corticotropin-releasing factor decreases vasogenic brain edema.

Authors:  J Tjuvajev; H Uehara; R Desai; B Beattie; C Matei; Y Zhou; M J Kreek; J Koutcher; R Blasberg
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury.

Authors:  E T Wei; G C Gao
Journal:  Regul Pept       Date:  1991-04-25

8.  Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.

Authors:  R S Leff; J M Thompson; M B Daly; D B Johnson; E A Harden; R J Mercier; G L Messerschmidt
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

Review 9.  Corticorelin acetate injections for the treatment of peritumoral brain edema.

Authors:  Jennifer A Moliterno; Euphael Henry; Susan C Pannullo
Journal:  Expert Opin Investig Drugs       Date:  2009-09       Impact factor: 6.206

10.  The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

Authors:  G P Chrousos; H M Schulte; E H Oldfield; P W Gold; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

View more
  13 in total

1.  The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.

Authors:  Rachel Grossman; Michelle A Rudek; Harry Brastianos; Patti Zadnik; Henry Brem; Betty Tyler; Jaishri O Blakeley
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-27       Impact factor: 3.333

2.  A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.

Authors:  Markus M Luedi; Sanjay K Singh; Jennifer C Mosley; Masumeh Hatami; Joy Gumin; Erik P Sulman; Frederick F Lang; Frank Stueber; Pascal O Zinn; Rivka R Colen
Journal:  J Neurosurg Anesthesiol       Date:  2017-01       Impact factor: 3.956

Review 3.  Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Authors:  Nils D Arvold; Terri S Armstrong; Katherine E Warren; Susan M Chang; Lisa M DeAngelis; Jaishri Blakeley; Marc C Chamberlain; Erin Dunbar; Herbert H Loong; David R Macdonald; David A Reardon; Michael A Vogelbaum; Ying Yuan; Michael Weller; Martin van den Bent; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

Review 4.  Key role of CRF in the skin stress response system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Desmond J Tobin; Theoharis C Theoharides; Jean Rivier
Journal:  Endocr Rev       Date:  2013-08-12       Impact factor: 19.871

5.  The effects of antiepileptic drugs on the growth of glioblastoma cell lines.

Authors:  Ching-Yi Lee; Hung-Yi Lai; Angela Chiu; She-Hung Chan; Ling-Ping Hsiao; Shih-Tseng Lee
Journal:  J Neurooncol       Date:  2016-01-13       Impact factor: 4.130

6.  Apatinib in refractory radiation-induced brain edema: A case report.

Authors:  Wei Guo Hu; Yi Ming Weng; Yi Dong; Xiang Pan Li; Qi-Bin Song
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

7.  Human corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human glioma.

Authors:  Yan Feng; Liqun Wang; Xin Liu; Qiang Wu; Haofeng Zhang; Fuguang Hu; Xiaofeng Sun
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

Review 8.  The Role of Urocortins in Intracerebral Hemorrhage.

Authors:  Ker Woon Choy; Andy Po-Yi Tsai; Peter Bor-Chian Lin; Meng-Yu Wu; Chihyi Lee; Aspalilah Alias; Cheng-Yoong Pang; Hock-Kean Liew
Journal:  Biomolecules       Date:  2020-01-07

9.  The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.

Authors:  Yuanyuan Xu; Ming Shen; Yiming Li; Ying Sun; Yanwei Teng; Yi Wang; Yourong Duan
Journal:  Oncotarget       Date:  2016-04-12

10.  Effects of dexamethasone on C6 cell proliferation, migration and invasion through the upregulation of AQP1.

Authors:  Ying Guan; Jianqiang Chen; Yuefu Zhan; Hong Lu
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.